GlassScriptPhysician profile
Ravi Pande
NPI 1326008913
$1,082.75
in general payments reported to CMS, 2019-2025
16 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $107 · 2021: $250 · 2022: $185 · 2023: $154 · 2024: $149 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $429.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $209.27 | 2023-2025 | Mavenclad |
| Janssen Pharmaceuticals, INC | $133.23 | 2022 | |
| Alexion Pharmaceuticals, INC. | $103.22 | 2021-2024 | Ultomiris |
| Lundbeck LLC | $97.50 | 2021 | |
| Sk Life Science, INC. | $90.81 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $86.11 | 2019 | |
| Biogen, INC. | $84.72 | 2020-2025 | Vumerity |
| Amgen INC. | $83.72 | 2019-2025 | Uplizna |
| Stemline Therapeutics INC. | $42.53 | 2024-2025 | Orserdu |
| Edwards Lifesciences Corporation | $36.50 | 2022 | |
| Novartis Pharmaceuticals Corporation | $29.57 | 2024 | |
| Medtronic, INC. | $24.52 | 2024 | Linq II |
| Takeda Pharmaceuticals U.S.A., INC. | $18.62 | 2025 | Iclusig |
| Celgene Corporation | $16.79 | 2021 | |
| Genentech USA, INC. | $12.92 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $12.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Pande listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.